Fig 1: TGD inhibits ROS generation and elevates NO production. (A) CCK-8 assays in TEV-1 cells treated with TGD at 25 mg/ml (L), 50 mg/ml (M) or 100 mg/ml (H) for 12, 24 or 48 h (B) CCK-8 assays in TEV-1 cells treated with H2O2 at 150 µM, 300 µM or 500 µM for 3 h or 6 h (C) Relative ROS levels in TEV-1 cells treated with H2O2 at 150 µM, 300 µM or 500 µM for 3 h or 6 h (D) Relative ROS levels in TEV-1 cells in the presence or absence of 500 µM H2O2 for 3 h and then treated with TGD at 25 mg/ml for 12 h or 24 h (E) Relative NO levels in TEV-1 cells in the presence or absence of 500 µM H2O2 for 3 h and then treated with TGD at 25 mg/ml for 12 h or 24 h (F) Relative (to Normal) mRNA levels of ICAM1 and sFLT1 in placental explants from women with normal pregnancy (Normal) or PE. (G) Relative mRNA levels of ICAM1 and sFLT1 in TEV-1 cells treated with or without TGD at 25 mg/ml for 24 h (H) Western blot analysis for cGMP, ICAM1 and sFLT1 in TEV-1 cells treated with or without TGD at 25 mg/ml for 24 h (I) Quantification via densitometry (n = 3) and statistical analysis of bands of (H). (J) Relative activities of CAT, SOD, GSH-PX and MDA in TEV-1 cells treated with or without TGD at 25 mg/ml for 24 h.